Stocks
Scribe Therapeutics Inc.SCTX
NASDAQHealthcareBiotechnology$17.33
Price as of · delayed, not real-time
A gene editing company focused on developing CRISPR-based therapies for serious diseases, particularly in oncology and genetic disorders. Its proprietary CRISPR platform aims to improve the precision and efficiency of gene editing, and investors track it for its potential to advance next-generation cell therapies.
52W Range: $13.50-$39.60
Congressional Interest in Scribe Therapeutics Inc. (SCTX)
No congressional trades have been disclosed for Scribe Therapeutics Inc. (SCTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading SCTX?
No congressional trades found for this stock.